Tiziana Crepaldi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8813705/publications.pdf

Version: 2024-02-01

63 papers	7,364 citations	218592 26 h-index	133188 59 g-index
67 all docs	67 docs citations	67 times ranked	16618 citing authors

#	Article	IF	Citations
1	Identification of novel circulating microRNAs in advanced heart failure by nextâ€generation sequencing. ESC Heart Failure, 2021, 8, 2907-2919.	1.4	22
2	Factor XII protects neurons from apoptosis by epidermal and hepatocyte growth factor receptorâ€dependent mechanisms. Journal of Thrombosis and Haemostasis, 2021, 19, 2235-2247.	1.9	2
3	HGF and MET: From Brain Development to Neurological Disorders. Frontiers in Cell and Developmental Biology, 2021, 9, 683609.	1.8	47
4	Engineering, Characterization, and Biological Evaluation of an Antibody Targeting the HGF Receptor. Frontiers in Immunology, 2021, 12, 775151.	2.2	2
5	Two-Chains Tissue Plasminogen Activator Unifies Met and NMDA Receptor Signalling to Control Neuronal Survival. International Journal of Molecular Sciences, 2021, 22, 13483.	1.8	8
6	The Long-Lasting Protective Effect of HGF in Cardiomyoblasts Exposed to Doxorubicin Requires a Positive Feed-Forward Loop Mediated by Erk1,2-Timp1-Stat3. International Journal of Molecular Sciences, 2020, 21, 5258.	1.8	5
7	Activation of the <scp>MET</scp> receptor attenuates doxorubicinâ€induced cardiotoxicity in vivo and in vitro. British Journal of Pharmacology, 2020, 177, 3107-3122.	2.7	20
8	Molecular Engineering Strategies Tailoring the Apoptotic Response to a MET Therapeutic Antibody. Cancers, 2020, 12, 741.	1.7	3
9	ERK: A Key Player in the Pathophysiology of Cardiac Hypertrophy. International Journal of Molecular Sciences, 2019, 20, 2164.	1.8	168
10	Hepatocyte Growth Factor Receptor. , 2018, , 2341-2351.		0
11	A New Transgenic Mouse Model of Heart Failure and Cardiac Cachexia Raised by Sustained Activation of Met Tyrosine Kinase in the Heart. BioMed Research International, 2016, 2016, 1-13.	0.9	10
12	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	4.3	4,701
13	Cardiac concentric hypertrophy promoted by activated Met receptor is mitigated in vivo by inhibition of Erk1,2 signalling with Pimasertib. Journal of Molecular and Cellular Cardiology, 2016, 93, 84-97.	0.9	12
14	Hepatocyte Growth Factor-mediated satellite cells niche perturbation promotes development of distinct sarcoma subtypes. ELife, 2016, 5, .	2.8	5
15	Hepatocyte Growth Factor Receptor. , 2016, , 1-11.		0
16	Cellular and molecular mechanisms of HGF/Met in the cardiovascular system. Clinical Science, 2015, 129, 1173-1193.	1.8	112
17	Anti-Differentiation Effect of Oncogenic Met Receptor in Terminally-Differentiated Myotubes. Biomedicines, 2015, 3, 124-137.	1.4	3
18	HGF/Met Axis in Heart Function and Cardioprotection. Biomedicines, 2014, 2, 247-262.	1.4	32

#	Article	IF	Citations
19	Agonist antibodies activating the Met receptor protect cardiomyoblasts from cobalt chloride-induced apoptosis and autophagy. Cell Death and Disease, 2014, 5, e1185-e1185.	2.7	61
20	MicroRNAs in myocardial ischemia: identifying new targets and tools for treating heart disease. New frontiers for miR-medicine. Cellular and Molecular Life Sciences, 2014, 71, 1439-1452.	2.4	34
21	Gene expression profiling of HGF/Met activation in neonatal mouse heart. Transgenic Research, 2013, 22, 579-593.	1.3	12
22	Digoxin and ouabain induce the efflux of cholesterol via liver X receptor signalling and the synthesis of ATP in cardiomyocytes. Biochemical Journal, 2012, 447, 301-311.	1.7	27
23	Signaling to Cardiac Hypertrophy: Insights from Human and Mouse RASopathies. Molecular Medicine, 2012, 18, 938-947.	1.9	39
24	A mouse model for spatial and temporal expression of HGF in the heart. Transgenic Research, 2011, 20, 1203-1216.	1.3	8
25	Novel therapy for myocardial infarction: can HGF/Met be beneficial?. Cellular and Molecular Life Sciences, 2011, 68, 1703-1717.	2.4	42
26	Activated Met Signalling in the Developing Mouse Heart Leads to Cardiac Disease. PLoS ONE, 2011, 6, e14675.	1.1	15
27	Cytolitic Activity of Monoclonal Antibodies Strongly Depends on Rabbit Complement Used. Tissue Antigens, 2008, 17, 368-371.	1.0	8
28	Bortezomib-mediated proteasome inhibition as a potential strategy for the treatment of rhabdomyosarcoma. European Journal of Cancer, 2008, 44, 876-884.	1.3	27
29	Hepatocyte Growth Factor Regulates Migration of Olfactory Interneuron Precursors in the Rostral Migratory Stream through Met-Grb2 Coupling. Journal of Neuroscience, 2008, 28, 5901-5909.	1.7	59
30	An In vivo Model of Met-Driven Lymphoma as a Tool to Explore the Therapeutic Potential of Met Inhibitors. Clinical Cancer Research, 2008, 14, 2220-2226.	3.2	15
31	Hepatocyte Growth Factor Acts as a Motogen and Guidance Signal for Gonadotropin Hormone-Releasing Hormone-1 Neuronal Migration. Journal of Neuroscience, 2007, 27, 431-445.	1.7	71
32	Ghrelin and Des-Acyl Ghrelin Promote Differentiation and Fusion of C2C12 Skeletal Muscle Cells. Molecular Biology of the Cell, 2007, 18, 986-994.	0.9	191
33	Conditional Activation of MET in Differentiated Skeletal Muscle Induces Atrophy. Journal of Biological Chemistry, 2007, 282, 6812-6822.	1.6	24
34	The oncogenic transcription factor PAX3-FKHR can convert fibroblasts into contractile myotubes. Experimental Cell Research, 2007, 313, 2308-2317.	1.2	16
35	Validation of Met as a Therapeutic Target in Alveolar and Embryonal Rhabdomyosarcoma. Cancer Research, 2006, 66, 4742-4749.	0.4	144
36	RNAi technology and lentiviral delivery as a powerful tool to suppress Tpr-Met-mediated tumorigenesis. Cancer Gene Therapy, 2005, 12, 456-463.	2.2	34

#	Article	IF	Citations
37	Analysis ofMlc-lacZ Met mutants highlights the essential function of Met for migratory precursors of hypaxial muscles and reveals a role for Met in the development of hyoid arch-derived facial muscles. Developmental Dynamics, 2004, 231, 582-591.	0.8	44
38	Ligand-regulated Binding of FAP68 to the Hepatocyte Growth Factor Receptor. Journal of Biological Chemistry, 2001, 276, 46632-46638.	1.6	32
39	Effect of hepatocyte growth factor on assembly of zonula occludens-1 protein at the plasma membrane. Journal of Cellular Physiology, 1998, 176, 465-471.	2.0	45
40	Ezrin Is an Effector of Hepatocyte Growth Factorâ€"mediated Migration and Morphogenesis in Epithelial Cells. Journal of Cell Biology, 1997, 138, 423-434.	2.3	290
41	Overexpression of c-met protooncogene product and raised Ki67 index in hepatocellular carcinomas with respect to benign liver conditions. Hepatology, 1995, 21, 1543-1546.	3.6	35
42	Overexpression of c-met protooncogene product and raised Ki67 index in hepatocellular carcinomas with respect to benign liver conditions*1. Hepatology, 1995, 21, 1543-1546.	3.6	6
43	Targeting of the SF/HGF receptor to the basolateral domain of polarized epithelial cells.. Journal of Cell Biology, 1994, 125, 313-320.	2.3	125
44	Overexpression of theMET/HGF receptor in ovarian cancer. International Journal of Cancer, 1994, 58, 658-662.	2.3	208
45	QUANTITATIVE EXPRESSION OF HLA CLASS I MOLECULES IN ACUTE NON-LYMPHOBLASTIC LEUKAEMIA CELLS. International Journal of Immunogenetics, 1993, 20, 165-173.	1.2	3
46	C-terminal truncated forms of Met, the hepatocyte growth factor receptor.. Molecular and Cellular Biology, 1991, 11, 5954-5962.	1.1	165
47	Activated human T cells express Î²2â€microglobulinâ€associated HLAâ€A,B,C molecules not recognized by W6/32 mAb. Tissue Antigens, 1991, 37, 138-140.	1.0	4
48	The receptor encoded by the human C-MET oncogene is expressed in hepatocytes, epithelial cells and solid tumors. International Journal of Cancer, 1991, 49, 323-328.	2.3	295
49	Chronic active hepatitis B. Interferonâ€activated natural killerâ€like cells against a hepatoma cell line transfected with the hepatitis B virus nucleic acid. Liver, 1991, 11, 106-113.	0.1	9
50	IEF ANALYSIS OF HLA MOLECULES IMMUNOPRECIPITATED BY PUTATIVE ANTI-CLASS I-LIKE ALLOANTISERA. International Journal of Immunogenetics, 1990, 17, 409-413.	1.2	1
51	Expression of HLA class I antigens in human tumors and their involvement in tumor growth. Research in Clinic and Laboratory, 1990, 20, 85-93.	0.3	6
52	Expression of class I - like alloantigens on leukemic cells is not correlated with the amount of HLA-A, B, C molecules. Tissue Antigens, 1988, 31, 270-273.	1.0	1
53	A NEW DUPLICATION AT THE C4B LOCUS ASSOCIATED WITH THE HLA-Aw68, Cw8, Bw65 HAPLOTYPE. International Journal of Immunogenetics, 1988, 15, 239-241.	1.2	3
54	NEW HLA CLASS I-LIKE ALLOANTIGENS EXPRESSED ON BLAST CELLS. International Journal of Immunogenetics, 1987, 14, 219-229.	1.2	6

#	Article	IF	Citations
55	HLA class Iâ€•like antigen expression on human leukemic cells. Tissue Antigens, 1987, 30, 76-83.	1.0	4
56	EQUINE T LYMPHOCYTES EXPRESS MHC CLASS II ANTIGENS. International Journal of Immunogenetics, 1986, 13, 349-360.	1.2	58
57	Alloantisera with apparent HLA-A specificity reacting only against phytohemagglutinin-activated cells. Research in Clinic and Laboratory, 1986, 16, 449-456.	0.3	5
58	Further antigenic determinants on HLAâ€A molecules. Tissue Antigens, 1985, 25, 69-74.	1.0	2
59	The monoclonal antibody AC1.59 defines a new polymorphic determinant on HLAâ€DR molecules. Tissue Antigens, 1985, 26, 25-34.	1.0	11
60	Contribution of monoclonal antibodies to the study of HLA class I antigens. Research in Clinic and Laboratory, 1984, 14, 287-95.	0.3	0
61	New HLA antigenic determinant shared by A2 and a subtype of Bw16 molecules detected by a monoclonal antibody. Human Immunology, 1983, 7, 17-23.	1.2	10
62	Characterization by monoclonal antibodies of lymphocyte subsets present in Bâ€enriched suspensions. Tissue Antigens, 1982, 20, 282-288.	1.0	2
63	A xenogeneic monoclonal antibody recognizing specificities controlled byHLA-A andB alleles. Immunogenetics, 1981, 12, 615-626.	1.2	15